BioPhotas Unveils MYSTIQUE, a Triple-Threat LED Mask for Skin and Hair

TUSTIN, CA – April 17, 2026 – On its 15th anniversary, therapeutic light therapy leader BioPhotas, Inc. has announced a significant new entry into the booming at-home beauty device market: the Celluma MYSTIQUE. The company claims it is the first FDA-cleared LED mask designed to treat acne, facial wrinkles, and scalp hair loss in a single, flexible device, aiming to set a new benchmark for efficacy and convenience.

The launch marks a strategic move for the maker of the award-winning Celluma SERIES, stepping into the highly competitive LED mask arena with a product that promises to address multiple consumer concerns simultaneously.

A New Category of Multi-Tasking Treatment

The Celluma MYSTIQUE enters a market crowded with established players like Dr. Dennis Gross, Omnilux, and CurrentBody. However, BioPhotas is carving out a unique niche by securing FDA clearance for a trio of the most common aesthetic concerns: acne, wrinkles, and androgenetic alopecia (hair loss). While many competitors offer masks cleared for wrinkles and acne, often requiring separate devices or modes, the MYSTIQUE’s clearance for hair loss in the same unit is a significant differentiator.

The device features five distinct treatment protocols and, according to the company, can run two treatments simultaneously. This dual-capability allows a user to address facial skin concerns while also treating hair loss on the scalp during a single session. This functionality is powered by what the company describes as the same advanced electronics found in its professional-grade panel devices.

A key technological feature is the device's patented, flexible, shape-taking design. Unlike rigid masks, the MYSTIQUE is engineered to conform closely to the contours of the face and head. This flexibility is crucial for effective light therapy, as the amount of energy delivered to the skin (irradiance) diminishes significantly with distance. By minimizing the gap between the LEDs and the target tissue, the design aims to ensure a consistent and effective dose of light energy is delivered across the entire treatment area.

"Our users have been asking us for years: 'When is Celluma going to make an LED mask?'" said Patrick Johnson, BioPhotas Chairman and Chief Innovation Officer, in a statement. "Our answer has always been: 'When we can make a Celluma mask.' That is exactly what we've accomplished with Celluma MYSTIQUE."

Navigating a Market of Hype and Science

Johnson’s comment highlights a core challenge in the consumer light therapy space: distinguishing scientifically validated devices from marketing-driven gadgets. The market has grown rapidly, particularly since the pandemic, leading to a flood of products with bold claims but often lacking the rigorous testing and regulatory oversight of medical-grade equipment.

BioPhotas is positioning the MYSTIQUE as a direct response to this trend. The company emphasizes that the new mask is not just a consumer-friendly form factor but an extension of its core technology, which has been built on clinical validation and regulatory compliance for 15 years. Curtis Cluff, the company's CEO, stressed that the MYSTIQUE is "built on proven technology, designed by our engineering team in California, and manufactured in the United States with our North American partners."

This commitment to FDA clearance and domestic manufacturing is a key part of BioPhotas's strategy to differentiate itself. Obtaining FDA clearance is a complex and resource-intensive process that requires manufacturers to provide evidence of a device's safety and effectiveness for its intended use. For consumers, this clearance provides a level of assurance that is often absent in a largely unregulated market. The MYSTIQUE's specific clearances for acne, wrinkles, and hair loss suggest the company has submitted substantial data to the agency to support these multi-faceted claims.

Global Ambitions Backed by Regulatory Strategy

With the U.S. launch underway, BioPhotas has already set its sights on international markets. The company announced it expects regulatory registration for the MYSTIQUE in the United Kingdom, the European Union, Canada, and Mexico in the coming weeks. This ambitious expansion plan underscores the global demand for advanced at-home aesthetic treatments.

Navigating this international regulatory landscape is a complex undertaking. In the post-Brexit UK, devices require registration with the Medicines and Healthcare products Regulatory Agency (MHRA). For the 27-nation EU, compliance with the stringent Medical Device Regulation (EU MDR) is mandatory, a process known for its rigorous requirements for clinical evidence and oversight by a Notified Body.

Similarly, market entry into Canada requires licensing from Health Canada, which often involves compliance with the Medical Device Single Audit Program (MDSAP), a unified standard recognized by several countries. In Mexico, approval from the regulatory body COFEPRIS is necessary, a process that can be streamlined if a device already has FDA approval but still requires a local registration holder and Spanish-language labeling. BioPhotas's confident timeline suggests a well-prepared regulatory strategy has been in motion for some time, leveraging its existing FDA clearances to expedite entry into these key markets.

The Celluma MYSTIQUE is available for pre-order with a special introductory price of $795, with a planned full retail price of $895. The company anticipates shipping U.S. orders by the end of May 2026, bringing a new, powerful multi-tasking tool to consumers seeking professional-grade results at home.